[cs_content][cs_element_section _id=”1″ ][cs_element_row _id=”2″ ][cs_element_column _id=”3″ ][cs_element_text _id=”4″ ][cs_content_seo]Dr Giselle Sholler
Chair, Beat Childhood Cancer
I am currently the Endowed Haworth Family Director of the Innovative Therapeutics Clinic and Director of Pediatric Oncology Research, and Head of the Pediatric Oncology Translational Research Laboratory at Levine Children’s Hospital. I am Associate Professor at Michigan State University College of Human Medicine.  The support and infrastructure of these institutions and their dedication to children creates an environment where innovative research and therapies can be brought forward to children.\n\n[/cs_content_seo][/cs_element_column][cs_element_column _id=”5″ ][cs_element_image _id=”6″ ][/cs_element_column][/cs_element_row][cs_element_row _id=”7″ ][cs_element_column _id=”8″ ][cs_element_accordion _id=”9″ ][cs_element_accordion_item _id=”10″ ][cs_content_seo]Background\n\n As the chair and lead investigator of the Beat Childhood Cancer consortium (formerly NMTRC) and through preclinical work done within my laboratory, I have successfully opened 18 Phase I and II trials for relapsed or refractory medulloblastoma and neuroblastoma patients as well trials using Molecular Guided Therapy in children with relapsed cancers.
The Beat Childhood Cancer consortium is a collaborative team of 40 universities and children’s hospitals that have joined together to offer a national network of clinical trials. I am committed to developing novel therapies and to working closely with collaborating investigators to share and perform innovative laboratory research leading to clinical trials.
My laboratory focus is primarily in the study of DFMO in neuroblastoma complementing our interest in this for maintenance therapy for neuroblastoma for which we have opened 5 clinical trials. Further understanding of this drugs mechanism and combination therapies will help guide further studies. I have a strong track record of working closely with investigators studying neuroblastoma and other pediatric cancers and this collaborative environment provides the constant availability of innovative perspectives that drives my research forward and ultimately makes a difference in the daily lives of children living with cancer.\n\n[/cs_content_seo][cs_element_accordion_item _id=”11″ ][cs_content_seo]Selected Peer-Reviewed Publications\n\n
Giselle L. Saulnier Sholler, William Ferguson, Genevieve Bergendahl, Jeffrey P. Bond, Kathleen Neville, Don Eslin, Valerie Brown, William Roberts, Randal K. Wada, Javier Oesterheld, Deanna Mitchell, Jessica Foley, Nehal S. Parikh, Francis Eshun, Peter Zage, Jawhar Rawwas, Susan Sencer, Debra Pankiewicz, Monique Quinn, Maria Rich, Joseph Junewick, Jacqueline M. Kraveka, Maintenance DFMO Increases Survival in High Risk Neuroblastoma, Scientific Reports, Sept 27,2018, 8:14445 | DOI:10.1038/s41598-018-32659-w
Cornelius A, Foley J, Bond J, Nagulapally AB, Steinbrecher J, Hendricks WPD, Rich M, Yendrembam S, Bergendahl G, Trent JM and Giselle S. Sholler, Molecular Guided Therapy Provides Sustained Clinical Response in Refractory Choroid Plexus Carcinoma, Frontiers in Pharmacology, Sept 25, 2017,  https://doi.org/10.3389/fphar.2017.00652
Zhao P, Hall J, Durston M, Voydanoff A, VanSickle E, Kelly S, Nagulapally, AB, Bond, J, Saulnier Sholler, G, BKM120 induces apoptosis and inhibits tumor growth in medulloblastoma. PLoS ONE  June 29, 2017, 12(6): e0179948. https://doi.org/10.1371/journal.pone.0179948
Rich M, Zhao P, Nagulapally A, Bond J, Saulnier Sholler G. Inhibition of Neuroblastoma Cell Growth by Difluoromethylornithine (DFMO) and Bortezomib through Suppression of LIN28 and MYCN, Journal of Cancer Therapy, June 2017, 8, 561-578
Maser T, Rich M, Hayes D, Zhao P, Nagulapally AB, Bond J, Saulnier Sholler G. Tolcapone induces oxidative stress leading to apoptosis and inhibition of tumor growth in Neuroblastoma, Cancer Med. 2017 Apr 21. doi: 10.1002/cam4.1065. [Epub ahead of print]
Mitchell D, Bergendahl G, Ferguson W, Roberts W, Higgins T, Ashikaga T, DeSarno M, Kaplan J, Kraveka J, Eslin D, Werff AV, Hanna GK, Saulnier Sholler GL, A Phase 1 Trial of TPI 287 as a Single Agent and in Combination With Temozolomide in Patients with Refractory or Recurrent Neuroblastoma or Medulloblastoma, Pediatr Blood Cancer. 2016 Jan;63(1):39-46.
Sun Y, Saulnier Sholler GL, Shukla GS, Pero SC, Carman CL, Zhao P, Krag DN Autologous antibodies that bind neuroblastoma cells, J Immunol Methods. 2015 Jul 23. pii: S0022-1759(15)30025-9. doi: 10.1016/j.jim.2015.07.009. [Epub ahead of print]
Saulnier Sholler GL, Gerner EW, Bergendahl G, MacArthur RB, VanderWerff A, Ashikaga T, et al. (2015) A Phase I Trial of DFMO Targeting Polyamine Addiction in Patients with Relapsed/Refractory Neuroblastoma. PLoS ONE 10(5): e0127246. doi:10.1371/journal.pone.0127246
Saulnier Sholler GL, Bond J, Bergendahl G, Dutta A, Dragon J, Neville K, Ferguson W, Roberts W, Eslin D, Kraveka J, Kaplan J, Mitchell D, Parikh N, Merchant M, Ashikaga T, Hanna G, Lescault PJ, Siniard A, Corneveaux J, Huentelman M, Trent J, Feasibility of implementing molecular-guided therapy for the treatment of patients with relapsed or refractory neuroblastoma, Cancer Medicine, http://onlinelibrary.wiley.com/doi/10.1002/cam4.436/ful
A. M. Lozier, M. E. Rich, A. P. Grawe, A. S. Peck, P. Zhao, A. Ting-Tung Chang, J. P. Bond, G. Saulnier Sholler, Targeting ornithine decarboxylase reverses the LIN28/Let-7 axis and inhibits glycolytic metabolism in neuroblastoma. Oncotarget 6(1): 196-206 (2014)
Heather M. Calderone, Akshita Dutta, Lauren Smith, Alexandra Eckardt, Ping Zhao, Giselle Saulnier Sholler, YM155 Inhibits Neuroblastoma Cell Migration and Survival in Vitro and Tumor Growth and Metastatic Burden in a Pre-Clinical Model. Journal of Cancer Therapy, Nov 2014 online: http://www.scirp.org/journal/jct
Saulnier Sholler GL, Currier E, Dutta A, Slavik M, Illenye S, Mendonca MC, Dragon J, Roberts S, Bond JP, PCI-24781 (abexinostat), a novel histone deacetylase inhibitor, induces reactive oxygen species-dependent apoptosis and is synergistic with bortezomib in neuroblastoma. J Cancer Ther Res 2014 (accepted)
Saulnier Sholler GL, Erika A. Currier, Akshita Dutta, Marni A. Slavik , Sharon A. Illenye, Maria Cecilia F. Mendonca, Julie A Dragon, Stephen S. Roberts and Jeffrey P. Bond, PCI-24781 (abexinostat), a novel histone deacetylase inhibitor, induces reactive oxygen species-dependent apoptosis and is synergistic with bortezomib in neuroblastoma. Journal of Cancer Therapeutics and Research. 2013 Dec 28; 2(21) (http://www.hoajonline.com/journals/pdf/2049-7962-2-21.pdf)
Levy AS1, Pyke-Grimm KA, Lee DA, Palla SL, Naranjo A, Saulnier Sholler G, Gratias E, Maloney K, Parshankar F, Lee-Scott M, Beierle EA, Gow K, Kim GE, Hunger S, Smith FO, Horton TM J Mentoring in pediatric oncology: a report from the Children’s Oncology Group Young Investigator Committee. Pediatr Hematol Oncol. 2013 Aug;35(6):456-61.
Morgenstern DA, Marzouki M, Bartels U, Irwin MS, Sholler GL, Gammon J, Yankanah R, Wu B, Samson Y, Baruchel S. Phase I study of vinblastine and sirolimus in pediatric patients with recurrent or refractory solid tumors. Pediatr Blood Cancer. 2013 Aug 17. doi: 10.1002/pbc.24656. [Epub ahead of print]
Samal K, Zhao P, Kendzicky A, Yco LP, McClung H, Gerner E, Burns M, Bachmann AS, Saulnier Sholler G. AMXT-1501, a novel polyamine transport inhibitor, synergizes with DFMO in inhibiting neuroblastoma cell proliferation by targeting both ornithine decarboxylase and polyamine transport.  Int J Cancer. 2013 Mar 2. doi: 10.1002/ijc.28139. [Epub ahead of print]
Eslin D, Sankpal U, Lee C, Sutphin R, Maliakal P, Currier E, Saulnier Sholler G, Khan M, and Basha R. In press. Tolfenamic acid inhibits neuroblastoma cell proliferation and induces apoptosis: a novel therapeutic agent for neuroblastoma. Mol Carcinog. 2013 May;52(5):377-86
Saulnier Sholler GL, Ferguson W, Bergendahl G, Currier E, Lenox SR, Bond J, Slavik M, Roberts W,  Mitchell D, Eslin D, Kraveka J, Kaplan J, Parikh N, Malempati S, Hanna G, Eugster E, Cherba D, Miller J, Webb C. A Pilot Trial Testing the Feasibility of Using Molecular-Guided Therapy in Patients with Recurrent Neuroblastoma. Journal of Cancer Therapy, 2012. 3(5): p. 602-612.
Bachmann AS, Geerts D, Saulnier Sholler G: Neuroblastoma: Ornithine decarboxylase and polyamines are novel targets for therapeutic intervention, In: Pediatric Cancer, Volume 1, Neuroblastoma: Diagnosis, Therapy, and Prognosis, Ed. Hayat MA, Springer, Heidelberg, Germany, 2012
Sun Y, Shukla G, Pero SC, Currier E, Saulnier Sholler G, Krag D.  Single tumor imaging with multiple antibodies targeting different antigens. Biotechniques. 2012 Apr;0(0):1-3.
Koto KS, Lescault P, Brard L, Kim K, Singh RK, Bond J, Illenye S, Slavik MA, Ashikaga T, Saulnier Sholler GL. Antitumor activity of nifurtimox is enhanced with tetrathiomolybdate in medulloblastoma. Int J Oncol, 38: 1329-1341 (2011).
Singh RK, Dorf L, DeMartino A, Illenye S, Koto K, Ashikaga T, Kim KK, Brard L, Saulnier Sholler GL. Oral RKS262 Reduces Tumor Burden in a Neuroblastoma (NB) Xenograft Animal Model and Mediates Cytotoxicity through SAPK/JNK and ROS Activation in Vitro. Cancer Biol Ther, 11(12): 1036-1045 (2011).
Saulnier Sholler GL, Bergendahl G, Brard L, Singh AP, Heath B, Bingham P, Ashikaga T, Kamen B, Homans A, Slavik MA, Lenox S, Higgins T, Ferguson W. A Phase I Study of Nifurtimox in Patients with Relapsed/Refractory Neuroblastoma, J Pediatr Hematol Oncol, 33(1): 25-30 (2011).
Lange TS, Zou Y, Singh RK, Kim KK, Kristjansdottir K, Saulnier Sholler GL, Brard L. Chemotherapeutic effect of calcidiol derivative B3CD in a neuroblastoma xenograft model. Chem Biol Drug Des, 76(2): 164-173 (2010). PMCID: PMC3024052.
Saulnier Sholler GL, Brard L, Straub J, Dorf L, Illyene S, Kalkunte S, Nishi R. Nifurtimox induces apoptosis of neuroblastoma cells in vitro and in vivo. J Pediatr Hematol Oncol, 31(3):187-193 (2009).
Brard L, Singh RK, Kim KK, Lange TS, Saulnier Sholler GL.  Induction of cytotoxicity, apoptosis and cell cycle arrest by 1-t-butyl carbamoyl, 7-methyl-indole-3-ethyl isothiocyanate (NB7M) in nervous system cancer cells. Drug Des Devel Ther, 2: 61-69 (2008). PMCID: PMC2761180.
Singh R, Lange TS, Kim K, Zou Y, Lieb C, Saulnier Sholler GL, Brard L. Effect of Indole Ethyl Isothiocyanates on Proliferation, Apoptosis and MAPK Signaling in Neuroblastoma Cell Lines. Bioorg Med Chem Lett, 17(21): 5846-5852 (2007). PMCID: PMC2093989.
Lange TS, Singh RK, Kim KK, Zou Y, Kalkunte SS, Saulnier Sholler GL, Swamy N, Brard L. Anti-proliferative and pro-apoptotic properties of 3-bromoacetoxy calcidiol in high-risk neuroblastoma. Chem Biol Drugs Des, 70(4): 302-310 (2007). PMCID: PMC2519607.
Straub J, Saulnier Sholler GL, Nishi R, Embryonic sympathoblasts transiently express TrkB in vivo and proliferate in response to brain-derived neurotrophic factor in vitro. BMC Dev Biol, 7: 10 (2007). PMCID: PMC1805739.
Saulnier Sholler GL, Kalkunte, S, Greenlaw, C, McCarten, K, Forman, E, Anti-Tumor activity of Nifurtimox observed in a patient with Neuroblastoma. J Pediatr Hematol Oncol, 10: 693-695 (2006).
Saulnier Sholler G, Luks F, Mangray S, Meech SJ. Advanced Small Cell Carcinoma of the Ovary in a Pediatric Patient with Long-Term Survival and Review of the Literature. J Pediatr Hematol Oncol, 27(3): 169-172 (2005).
Saulnier Sholler GL, Boney C. Regulation of Mitogenic Signaling by Nerve Growth Factor and Brain Derived   Nerve Factor in Neuroblastoma Cells. Pediatr Blood Cancer, 44(6): 545 (2005).